Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept versus adalimumab response factors in rheumatoid arthritis and spondyloarthritis
IRCT20240309061221N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Mar 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and spondyloarthritis (SpA) comparing Etanercept with Adalimumab (2 arms). Primary endpoints: Treatment response in rheumatoid arthritis and Treatment response in spondyloarthropathy. Started Mar 2021; status: completed.
02
Drugs
etanerceptadalimumab
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)spondyloarthritis (SpA)
Beyond the preview
Go deeper on IRCT20240309061221N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240309061221N1.